CTKB Stock Analysis: Cytek Biosciences | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 764m USD | 12M Return: 20.2% | US23285D1090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.14M
Qual. Beats: 1
Rev. Trend: 71.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.3 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Cytek Biosciences, Inc. (NASDAQ: CTKB) is a cell analysis solutions company that develops and sells flow cytometry instruments, imaging flow cytometers, reagents, and software used in biomedical research and clinical applications. Its product portfolio spans the Cytek Aurora, Northern Lights, and Aurora EVO spectral flow cytometry systems, the Amnis ImageStream imaging flow cytometers, and the Guava Muse and easyCyte flow cytometers, along with cFluor reagent kits, the Orion reagent cocktail preparation system, and SpectroFlo acquisition and analysis software. The company markets its offerings under the Amnis and Guava brand names and serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations (CROs).
The company distributes products through a direct sales force in North America, Europe, China, and the broader Asia-Pacific region, and through distributors in parts of Europe, Latin America, and the Middle East. Founded in 1992 and headquartered in Fremont, California, Cytek was formerly known as Cytoville, Inc. before adopting its current name in August 2015, and completed its IPO in July 2021.
As a life sciences tools provider in the healthcare equipment sub-industry, Cytek operates a combined razor-and-blade business model, selling capital instruments while generating recurring revenue from consumables such as cFluor antibody reagents and reagent kits. Flow cytometry is a widely adopted technique for analyzing cell characteristics in immunology, oncology, and drug discovery research.
- Reagent revenue growth drives recurring installed base expansion
- China sales exposure creates geopolitical and currency risk
- Competition from BD and Beckman Coulter pressures flow cytometry pricing
- Biotech R&D spending softness pressures instrument order growth
| Net Income: -81.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -1.83 > 1.0 |
| NWC/Revenue: 141.6% < 20% (prev 159.2%; Δ -17.59% < -1%) |
| CFO/TA -0.01 > 3% & CFO -6.59m > Net Income -81.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (130.4m) vs 12m ago 2.20% < -2% |
| Gross Margin: 54.75% > 18% (prev 53.46%; Δ 1.29% > 0.5%) |
| Asset Turnover: 44.13% > 50% (prev 39.77%; Δ 4.36% > 0%) |
| Interest Coverage Ratio: -25.15 > 6 (EBIT TTM -38.4m / Interest Expense TTM 1.53m) |
| A: 0.66 (Total Current Assets 378.9m - Total Current Liabilities 85.0m) / Total Assets 446.1m |
| B: -0.31 (Retained Earnings -138.9m / Total Assets 446.1m) |
| C: -0.08 (EBIT TTM -38.4m / Avg Total Assets 470.5m) |
| D: 2.58 (Book Value of Equity 321.4m / Total Liabilities 124.8m) |
| Altman-Z'' = 5.46 = AAA |
| DSRI: 0.93 (Receivables 60.8m/61.7m, Revenue 207.6m/196.8m) |
| GMI: 0.98 (GM 53.46% / 54.75%) |
| AQI: 0.52 (AQ_t 0.08 / AQ_t-1 0.16) |
| SGI: 1.05 (Revenue 207.6m / 196.8m) |
| TATA: -0.17 (NI -81.2m - CFO -6.59m) / TA 446.1m) |
| Beneish M = -3.36 (Cap -4..+1) = AA |
As of November 20, 2026, the stock is trading at USD 6.32 with a total of 2,180,769 shares traded. Over the past week, the price has changed by +14.49%, over one month by +20.38%, over three months by +34.47% and over the past year by +20.15%.
Current recommended Stop Loss: 5.90 (which is 6.6% or 1.3 ATR below the current price).
Cytek Biosciences has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CTKB.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.5 | 2.8% |
P/E Forward = 370.3704
P/S = 3.6783
P/B = 2.3768
Revenue TTM = 207.6m USD
EBIT TTM = -38.4m USD
EBITDA TTM = -26.5m USD
Long Term Debt = 99.0k USD (from longTermDebt, last quarter)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 40.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 16.2m
Net Debt = -215.0m USD (calculated: Debt 40.9m - CCE 255.9m)
Enterprise Value = 548.8m USD (763.8m + Debt 40.9m - CCE 255.9m)
Interest Coverage Ratio = -25.15 (Ebit TTM -38.4m / Interest Expense TTM 1.53m)
EV/FCF = -40.70x (Enterprise Value 548.8m / FCF TTM -13.5m)
FCF Yield = -2.46% (FCF TTM -13.5m / Enterprise Value 548.8m)
FCF Margin = -6.49% (FCF TTM -13.5m / Revenue TTM 207.6m)
Net Margin = -39.10% (Net Income TTM -81.2m / Revenue TTM 207.6m)
Gross Margin = 54.75% ((Revenue TTM 207.6m - Cost of Revenue TTM 94.0m) / Revenue TTM)
Gross Margin QoQ = 58.63% (prev 58.87%)
Tobins Q-Ratio = 1.23 (Enterprise Value 548.8m / Total Assets 446.1m)
Interest Expense / Debt = 3.73% (Interest Expense 1.53m / Debt 40.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -30.4m (EBIT -38.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.46 (Total Current Assets 378.9m / Total Current Liabilities 85.0m)
Debt / Equity = 0.13 (Debt 40.9m / totalStockholderEquity, last quarter 321.4m)
Debt / EBITDA = 8.12 (negative EBITDA) (Net Debt -215.0m / EBITDA -26.5m)
Debt / FCF = 15.94 (negative FCF - burning cash) (Net Debt -215.0m / FCF TTM -13.5m)
Total Stockholder Equity = 328.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.26% (Net Income -81.2m / Total Assets 446.1m)
RoE = -24.74% (Net Income TTM -81.2m / Total Stockholder Equity 328.2m)
RoCE = -11.71% (EBIT -38.4m / Capital Employed (Equity 328.2m + L.T.Debt 99.0k))
RoIC = -8.37% (negative operating profit) (NOPAT -30.4m / Invested Capital 362.6m)
WACC = 6.86% (E(763.8m)/V(804.7m) * Re(7.07%) + D(40.9m)/V(804.7m) * Rd(3.73%) * (1-Tc(0.21)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -36.14 | Cagr: -0.37%
[DCF] Fair Price = unknown (Cash Flow -13.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.40 | # QB: 1
Revenue Correlation: 71.12 | Revenue CAGR: 1.75% | SUE: 0.13 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.08 | Chg30d=+27.27% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.29 | Chg30d=+16.49% | Revisions=-40% | GrowthEPS=+44.9% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=-0.18 | Chg30d=+27.64% | Revisions=-50% | GrowthEPS=+36.0% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -67% (up=0, down=6)